SCHEMBL30869126

SCHEMBL30869126

CC(C)(C)OC(=O)NCCC(=O)Nc1cc(C2CCOCC2)cc2c1cnn2C1CCCCO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 5/20 0.40
▸ ALDH1A1 P00352 1/20 0.35
▸ RXRA P19793 1/20 0.34
▸ RXRB P28702 1/20 0.34
▸ RXRG P48443 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.33
▸ EPHX1 P07099 1/20 0.33
▸ PRMT5 O14744 1/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33
▸ FPR3 P25089 2/20 0.32
▸ FPR2 P25090 2/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ JAK1 P23458 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ MTOR P42345 1/20 0.31
▸ PIK3CG P48736 1/20 0.31
▸ SCN9A Q15858 1/20 0.31
▸ AKT1 P31749 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30869058 0.88 ATR (0.43) ATRRXRARXRBRXRGADORA3
SCHEMBL30869008 0.84 ATR (0.39) ATRALDH1A1RXRARXRBRXRG
SCHEMBL30797740 0.77 ATR (0.43) ATRALDH1A1RXRARXRBRXRG
SCHEMBL30869134 0.76 ATR (0.37) ATRRXRARXRBRXRGJAK2
SCHEMBL30869153 0.75 ATR (0.41) ATRALDH1A1RXRARXRBRXRG
SCHEMBL30797676 0.75 ATR (0.42) ATRALDH1A1RXRARXRBRXRG
SCHEMBL27378131 0.75 RXRA (0.39) ATRALDH1A1RXRARXRBRXRG
SCHEMBL30797598 0.75 RXRA (0.39) ATRALDH1A1RXRARXRBRXRG
SCHEMBL30797456 0.73 RXRA (0.38) ATRALDH1A1RXRARXRBRXRG
SCHEMBL27378138 0.73 ALDH1A1 (0.38) ATRALDH1A1RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTPR LTD (GB) 2026-03-26 — — US disclosed
EP-4584249-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS Cambridge Enterprise Limited (GB) 2025-07-16 — — EP disclosed
WO-2024052702-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085062-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CSNK1A1, CSNK1G1, CSNK2A3 ATR 984/4885ALDH1A1 3770/4885RXRA 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback